NCT01209325 · OUTCOME
Geometric Mean Titers for HPV 11
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males · Source last updated 2020-08-11
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- mMU/mL
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline through month 24
What was measured
Geometric mean concentration of antibodies for HPV 11 at each visit
Analysis population: Eligible participants who received at least one vaccination with evaluable serum assessments.
Groups in this outcome
HPV 11 Sero-negative at Baseline
Sero-negative for HPV 11 at baseline.
HPV 11 Sero-positive at Baseline
Sero-positive for HPV 11 at baseline
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 11 Sero-negative at Baseline | 79 |
|---|
| HPV 11 Sero-positive at Baseline | 64 |
|---|
Reported measurements
Baseline
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 11 Sero-negative at Baseline | 79 |
|---|
| HPV 11 Sero-positive at Baseline | 64 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 11 Sero-negative at Baseline | 0 | Not reported | 0 | 0 | Not reported |
|---|
| HPV 11 Sero-positive at Baseline | 42.7 | Not reported | 30.1 | 60.5 | Not reported |
|---|
Month 7
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 11 Sero-negative at Baseline | 71 |
|---|
| HPV 11 Sero-positive at Baseline | 56 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 11 Sero-negative at Baseline | 452.4 | Not reported | 378.1 | 541.4 | Not reported |
|---|
| HPV 11 Sero-positive at Baseline | 976.2 | Not reported | 757.5 | 1258.1 | Not reported |
|---|
Month 12
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 11 Sero-negative at Baseline | 67 |
|---|
| HPV 11 Sero-positive at Baseline | 51 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 11 Sero-negative at Baseline | 132.0 | Not reported | 102.7 | 169.8 | Not reported |
|---|
| HPV 11 Sero-positive at Baseline | 493.7 | Not reported | 355.2 | 686.1 | Not reported |
|---|
Month 18
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 11 Sero-negative at Baseline | 63 |
|---|
| HPV 11 Sero-positive at Baseline | 48 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 11 Sero-negative at Baseline | 89.6 | Not reported | 67.2 | 119.4 | Not reported |
|---|
| HPV 11 Sero-positive at Baseline | 373.2 | Not reported | 262.1 | 531.6 | Not reported |
|---|
Month 24
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 11 Sero-negative at Baseline | 60 |
|---|
| HPV 11 Sero-positive at Baseline | 44 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 11 Sero-negative at Baseline | 84.4 | Not reported | 62.1 | 114.9 | Not reported |
|---|
| HPV 11 Sero-positive at Baseline | 300.2 | Not reported | 205.8 | 438.1 | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- group Id
- OG001
- lower Limit
- 30.1
- upper Limit
- 60.5
- value
- 42.7
- denoms
- counts
- group Id
- OG000
- value
- 79
- group Id
- OG001
- value
- 64
- units
- Participants
- title
- Baseline
- categories
- measurements
- group Id
- OG000
- lower Limit
- 378.1
- upper Limit
- 541.4
- value
- 452.4
- group Id
- OG001
- lower Limit
- 757.5
- upper Limit
- 1258.1
- value
- 976.2
- denoms
- counts
- group Id
- OG000
- value
- 71
- group Id
- OG001
- value
- 56
- units
- Participants
- title
- Month 7
- categories
- measurements
- group Id
- OG000
- lower Limit
- 102.7
- upper Limit
- 169.8
- value
- 132.0
- group Id
- OG001
- lower Limit
- 355.2
- upper Limit
- 686.1
- value
- 493.7
- denoms
- counts
- group Id
- OG000
- value
- 67
- group Id
- OG001
- value
- 51
- units
- Participants
- title
- Month 12
- categories
- measurements
- group Id
- OG000
- lower Limit
- 67.2
- upper Limit
- 119.4
- value
- 89.6
- group Id
- OG001
- lower Limit
- 262.1
- upper Limit
- 531.6
- value
- 373.2
- denoms
- counts
- group Id
- OG000
- value
- 63
- group Id
- OG001
- value
- 48
- units
- Participants
- title
- Month 18
- categories
- measurements
- group Id
- OG000
- lower Limit
- 62.1
- upper Limit
- 114.9
- value
- 84.4
- group Id
- OG001
- lower Limit
- 205.8
- upper Limit
- 438.1
- value
- 300.2
- denoms
- counts
- group Id
- OG000
- value
- 60
- group Id
- OG001
- value
- 44
- units
- Participants
- title
- Month 24
- denoms
- counts
- group Id
- OG000
- value
- 79
- group Id
- OG001
- value
- 64
- units
- Participants
- description
- Geometric mean concentration of antibodies for HPV 11 at each visit
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Sero-negative for HPV 11 at baseline.
- id
- OG000
- title
- HPV 11 Sero-negative at Baseline
- description
- Sero-positive for HPV 11 at baseline
- id
- OG001
- title
- HPV 11 Sero-positive at Baseline
- param Type
- GEOMETRIC_MEAN
- population Description
- Eligible participants who received at least one vaccination with evaluable serum assessments.
- reporting Status
- POSTED
- time Frame
- Baseline through month 24
- title
- Geometric Mean Titers for HPV 11
- type
- SECONDARY
- unit Of Measure
- mMU/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle